Yuji Ikari1, Yuya Matsue2,3, Sho Torii1, Misaki Hasegawa1, Kazuki Aihara1, Shunsuke Kuroda4,5, Takahide Sano6,7, Takeshi Kitai8, Taishi Yonetsu9, Shun Kohsaka10, Takuya Kishi11, Issei Komuro12, Ken-Ichi Hirata13, Koichi Node14, Shingo Matsumoto6. 1. Department of Cardiology, Tokai University School of Medicine. 2. Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine. 3. Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine. 4. Department of Cardiology, Kameda Medical Center. 5. Department of Cardiovascular Medicine, Cleveland Clinic. 6. Department of Cardiovascular Medicine, Toho University Graduate School of Medicine. 7. Department of Cardiology, Ebara Hospital. 8. Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital. 9. Department of Interventional Cardiology, Tokyo Medical and Dental University. 10. Department of Cardiology, Keio University School of Medicine. 11. Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare. 12. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo. 13. Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine. 14. Department of Cardiovascular Medicine, Saga University.
Abstract
BACKGROUND: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. CONCLUSIONS: This study suggests the potential benefits of statins use against COVID-19.
BACKGROUND:Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19).Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. CONCLUSIONS: This study suggests the potential benefits of statins use against COVID-19.